---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000055"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T21:00:51.239663+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q3 2022: INGREZZA sales $376M, GAAP EPS $0.69; raises FY guidance

## Summary
- Q3 INGREZZA net product sales $376M (+31% YoY); TRx ~68,600 (+32% YoY).
- GAAP net income $68.5M ($0.69 diluted EPS); non-GAAP net income $106.7M ($1.08 EPS).
- Total revenue $387.9M, up 31% from $296.0M in Q3 2021.
- Raised 2022 INGREZZA sales guidance to $1.400-$1.425B; R&D & SG&A guidance reaffirmed.
- Acquired Diurnal Group plc for ~£48.3M (~$56M); sNDA for valbenazine in Huntington chorea submitted.

## SEC filing metadata
- accession: 0000914475-22-000055
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/nbix-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000055
- JSON: https://secwatch.observer/filing/0000914475-22-000055.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000055.txt

## Key facts
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC reported Third quarter ended September 30, 2022 results: revenue Total revenues $ 387.9, net income GAAP net income $ 68.5, EPS GAAP earnings per share – diluted $ 0.69.
  - Period: Third quarter ended September 30, 2022
  - Revenue: Total revenues $ 387.9
  - Net income: GAAP net income $ 68.5
  - EPS: GAAP earnings per share – diluted $ 0.69
  - Result: reported results
  source text: Total revenues $ 387.9 $ 296.0 $ 1,076.7 $ 821.5 GAAP Research and Development (R&D) $ 107.7 $ 92.7 $ 345.8 $ 240.7 Non-GAAP R&D $ 92.8 $ 80.7 $ 302.2 $ 204.5 GAAP Selling, General and Administrative (SG&A) $ 186.3 $ 154.6 $ 569.8 $ 426.8 Non-GAAP SG&A $ 158.1 $ 129.5 $ 483.8 $ 364.4 GAAP net income $ 68.5 $ 22.5 $ 65.5 $ 96.9 GAAP earnings per share – diluted $ 0.69 $ 0.23 $ 0.67 $ 0.99
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm
- Earnings Releases
  NEUROCRINE BIOSCIENCES INC reported Fiscal year 2022 results: revenue INGREZZA Net Product Sales 1 $ 1,400 $ 1,425. Guidance raised.
  - Period: Fiscal year 2022
  - Revenue: INGREZZA Net Product Sales 1 $ 1,400 $ 1,425
  - Guidance: raised
  - Result: guidance update
  source text: Updated 2022 INGREZZA Sales and Reaffirmed Operating Expense Guidance: Range (in millions) Low High INGREZZA Net Product Sales 1 $ 1,400 $ 1,425 GAAP R&D expense 2 $ 415 $ 450 Non-GAAP R&D expense 3 $ 360 $ 395 GAAP SG&A expense $ 720 $ 735 Non-GAAP SG&A expense 3 $ 605 $ 620 1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447522000055/0000914475-22-000055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.